Currently Viewing:
Evidence-Based Diabetes Management May 2015
Prevention of Type 2 Diabetes Requires BOTH Intensive Lifestyle Interventions and Population-Wide Approaches
Ann Albright, PhD, RD
Building Community-Clinical Linkages to Address the Diabetes Epidemic
Brenda Schmidt, MS, MBA
Real-World Evidence Mounts for Rivaroxaban
Andrew Smith
ADA, AMA, and YMCA Praise Introduction of Medicare Diabetes Prevention Act
Mary K. Caffrey
States With Medicaid Expansion Find 23% Rise in T2DM Diagnoses Among Enrollees, While Rest See No Increase
Mary K. Caffrey
USPSTF Evidence Review Could Lead to Revised Screening
Mary K. Caffrey
New Therapeutic Approach Did Not Reduce Scarring After Angioplasty
Mary K. Caffrey
At Joslin, We're Ready to Welcome the ADA to Boston
Robert A. Gabbay, MD, PhD
Preventing Ketoacidosis Complications in Diabetes
Surabhi Dangi-Garimella, PhD
More Young Adults Would Take Statins Under Pediatric Guidelines, Study Finds
Mary K. Caffrey
JAMA Study Reports Potential for Using Insulin to Prevent T1DM in High-Risk Children
Mary K. Caffrey
Toujeo and Afrezza: New and Improved Insulins, Limited by FDA Labeling Constraints
Andrew Smith
PROMISE Results Have Implications for Managed Care; May Change Guidelines, Put Pressure on Payers to Cover CTA
Mary K. Caffrey
Hospitals in Low-Income Areas Scored High in MI Care, Even if Patients Had Poor Outcomes
Mary K. Caffrey
Currently Reading
Losing Weight And Keeping it Off Can Free Patients From Atrial Fibrillation
Mary K. Caffrey
Personal Coaching Halts Progression to Diabetes in Some Patients, Study Finds
Mary K. Caffrey
Study of Heart Failure Patients Defines How Avoiding Risk Factors Can Add Years to Life
Mary K. Caffrey
PEGASUS Trial Shows Long-Term Benefits of Ticagrelor After Heart Attack
Mary K. Caffrey
Session Offers Cardiologists Insights Into New Payment Models, ACOs
Mary K. Caffrey
Cholesterol-Fighting Drug Evolocumab Also Reduces Cardiovascular Events, Study Finds
Mary K. Caffrey
Rivaroxaban Postmarketing Study Continues to Find Fatal Bleeds Are Rare
Mary K. Caffrey
Focusing on Prediabetes Is the Key to Reversing the Rise in Diabetes
Jonathan Lever

Losing Weight And Keeping it Off Can Free Patients From Atrial Fibrillation

Mary K. Caffrey
Coverage from the 64th Scientific Sessions of the American College of Cardiology.

Maintaining weight loss offers many health benefits, and a study presented on March 16, 2015, at the 64th Annual Meeting of the American College of Cardiology added another item to the list: obese patients with atrial fibrillation are far more likely to rid themselves of this heart ailment if they shed pounds.

For obese patients, weight loss might require support, as researchers of the LEGACY (Long-Term Effect of Goal-Directed Weight Management on an Atrial Fibrillation Cohort) study concluded. Support is worth providing, because the study found that if patients lost at least 10% of their body weight, they were 6 times more likely to achieve arrhythmiafree survival.


The study, led by Rajeev Pathak, MD, a cardiologist and fellow in electrophysi-ology at the University of Adelaide, Aus-tralia, was the first study to outline the benefits of sustained weight loss, the ef-fects of the amount of weight lost, and the impact of changes in weight over time among patients who suffered from atrial fibrillation (AF). This condition causes shortness of breath and muscle weakness, and can indicate stroke risk. Treatment typically includes anticoagulants, which can present their own risks in some patients.


“We found that sustained weight loss is achievable in obese patients and that it can significantly reduce the burden of atrial fibrillation,” Pathak said. Previous studies had examined only the short-term effects of weight loss on AF.

LEGACY researchers enrolled 355 par-ticipants in a weight loss clinic that pro-vided support through 3 in-person visits a month, nutrition guidance, exercise, counseling and a physical activity diary. All participants were obese (with a body mass index of at least 27 kg/m2) and had AF at the start of the study, and all agreed to participate, which Pathak ac-knowledged does pose some limitations to the results. Subjects with permanent AF, previous AF ablation, and severe medical illnesses were excluded.

Each year for 4 years, participants re-ported for a health exam and an assessment of their AF symptoms, based on their own reports and 7 days’ worth of readings from a Holter monitor. Patients also underwent an echocardiogram and sonogram to measure heart health.


As subjects progressed, they were categorized based on the percentage of body weight lost. Researchers also tracked patients’ AF symptoms, and the results showed that the burden of the condition decreased far more for those who lost the most weight, with both weight loss and weight fluctuation being independent predictors of outcomes. At the 4-year mark, 45% of patients who lost at least 10% of their weight, and 22% of those who lost 3% to 9% of the weight, were free of AF symptoms—without the need for surgery or medication. By con-trast, only 13% of patients who lost less than 3% of their weight were symptom-free without such treatments.


Both sustained weight management and an absence of weight fluctuation were associated with an absence of AF symptoms. Those who lost and regained more than 5% of weight between annu-al visits were twice as likely to experience symptoms. Stable weight loss also helped patients achieve improved blood pressure, cholesterol, and blood sugar levels. 

Reference

Pathak R, et al. Long-term effect of goal directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY Study). J Am Coll Cardiol. doi:101016/jacc.2015.03.002.

PDF
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up